Characterization of novel inhibitors of histone acetyltransferases

Modification of proteins by histone acetyltransferases (HAT) or histone deacetylases plays an important role in the control of gene expression, and its dysregulation has been linked to malignant transformation and other diseases. Although histone deacetylase inhibitors have been extensively studied and several are currently in clinical trials, there is little information available on inhibitors of HATs (HATi). Starting from the natural product lead HATi anacardic acid, a series of 28 analogues was synthesized and investigated for HAT-inhibitory properties and effects on cancer cell growth. The compounds inhibited up to 95% HAT activity in vitro, and there was a clear correlation between their inhibitory potency and cytotoxicity toward a broad panel of cancer cells. Interestingly, all tested compounds were relatively nontoxic to nonmalignant human cell lines. Western blot analysis of MCF7 breast carcinoma cells treated with HATi showed significant reduction in acetylation levels of histone H4. To directly show effect of the new compounds on HAT activity in vivo, MCF7 cells were cotransfected with the p21 promoter fused to firefly luciferase and a full-length p300 acetyltransferase, and luciferase activity was determined following treatment with HATi. Significant inhibition of p300 activity was detected after treatment with all tested compounds except one. Effects of the new HATi on protein acetylation and HAT activity in vivo make them a suitable tool for discovery of molecular targets of HATs and, potentially, for development of new anticancer therapeutics. [Mol Cancer Ther 2007;6(9):2391–8]

[1]  T. Iwama,et al.  p300 gene alterations in colorectal and gastric carcinomas. , 1996, Oncogene.

[2]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[3]  Yusuke Nakamura,et al.  Amplification and over‐expression of the AIB1 nuclear receptor co‐activator gene in primary gastric cancers , 2000, International journal of cancer.

[4]  Xiaofeng Jiang,et al.  Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation , 2006, FEBS letters.

[5]  C. Allis,et al.  Histone acetyltransferases. , 2001, Annual review of biochemistry.

[6]  E. Appella,et al.  Charge Modification at Multiple C-terminal Lysine Residues Regulates p53 Oligomerization and Its Nucleus-Cytoplasm Trafficking* , 2006, Journal of Biological Chemistry.

[7]  K. Tsujimoto,et al.  Synergistic effects of anacardic acids and methicillin against methicillin resistant Staphylococcus aureus. , 2004, Bioorganic & medicinal chemistry.

[8]  Tapas K. Kundu,et al.  Small Molecule Modulators of Histone Acetyltransferase p300* , 2003, Journal of Biological Chemistry.

[9]  P. Matthias,et al.  HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo , 2003, The EMBO journal.

[10]  Xiaofeng Jiang,et al.  The FATC Domains of PIKK Proteins Are Functionally Equivalent and Participate in the Tip60-dependent Activation of DNA-PKcs and ATM* , 2006, Journal of Biological Chemistry.

[11]  C. Glass,et al.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. , 2001, Human molecular genetics.

[12]  R. DePinho,et al.  PCAF Modulates PTEN Activity*♦ , 2006, Journal of Biological Chemistry.

[13]  T. Kundu,et al.  Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.

[14]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[15]  P. Cole,et al.  Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. , 2003, Bioorganic & medicinal chemistry.

[16]  Ian M Adcock,et al.  The Transcriptional Co-activators CREB-binding Protein (CBP) and p300 Play a Critical Role in Cardiac Hypertrophy That Is Dependent on Their Histone Acetyltransferase Activity* , 2003, The Journal of Biological Chemistry.

[17]  S. Ohta,et al.  Structure-antibacterial activity relationships of anacardic acids , 1993 .

[18]  R. Roeder,et al.  HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. , 2000, Molecular cell.

[19]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[20]  Athanassios Giannis,et al.  Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. , 2004, Angewandte Chemie.

[21]  N. L. La Thangue,et al.  Chromatin control and cancer-drug discovery: realizing the promise. , 2006, Drug discovery today.

[22]  S. Shobha,et al.  INHIBITION OF SOYBEAN LIPOXYGENASE-1 BY ANACARDIC ACIDS, CARDOLS, AND CARDANOLS , 1994 .

[23]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[24]  S. Berger,et al.  p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage , 1999, Molecular and Cellular Biology.

[25]  I. Kubo,et al.  Tyrosinase inhibitors from Anacardium occidentale fruits. , 1994, Journal of natural products.

[26]  B. Johansson,et al.  Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). , 2001, Human molecular genetics.

[27]  A. Srinivasa Rao,et al.  Synthesis of sildenafil analogues from anacardic acid and their phosphodiesterase-5 inhibition. , 2002, Journal of agricultural and food chemistry.

[28]  Andrew J. Bannister,et al.  Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity , 2005, Molecular Cancer Therapeutics.

[29]  Xiang-Jiao Yang.  The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. , 2004, Nucleic acids research.

[30]  Carlos Caldas,et al.  Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.

[31]  R. Aguiar,et al.  Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. , 1997, Blood.

[32]  Udaykumar Ranga,et al.  Curcumin, a Novel p300/CREB-binding Protein-specific Inhibitor of Acetyltransferase, Represses the Acetylation of Histone/Nonhistone Proteins and Histone Acetyltransferase-dependent Chromatin Transcription* , 2004, Journal of Biological Chemistry.

[33]  M. Jung,et al.  Chromatin Modifications as Targets for New Anticancer Drugs , 2005, Archiv der Pharmazie.

[34]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[35]  Xiaofeng Jiang,et al.  A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. , 2005, Proceedings of the National Academy of Sciences of the United States of America.